South Texas Accelerated Research Therapeutics-ko ikertzaileekin lankidetzan egindako argitalpenak (2)

2021

  1. Phase I Trial of Cemiplimab, Radiotherapy, Cyclophosphamide, and Granulocyte Macrophage Colony-Stimulating Factor in Patients with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

    Oncologist, Vol. 26, Núm. 9, pp. e1508-e1513

  2. Tolerability and antitumor activity of cemiplimab, a human monoclonal anti–PD-1, as monotherapy in patients with pretreated non-small cell lung cancer (NSCLC): Data from the Phase 1 NSCLC expansion cohort

    Lung Cancer, Vol. 155, pp. 151-155